Zhang Yue Wei, Ao Jin, Liu Ying, Qiao Ming Xi, Yang Xue Ling, Tang Shun Xiong, Li Chuang, Xu Ke
The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China.
Tumour Biol. 2014 Nov;35(11):10905-10. doi: 10.1007/s13277-014-2408-9. Epub 2014 Aug 2.
The objective of this study is to investigate pharmacokinetics of gelatin sponge microparticles (GSMs) combined with epirubicin in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization (TACE). Eighteen successful models of VX2 in New Zealand white rabbits was established, which were divided into three groups randomly: HAI group (n = 6), the epirubicin solution (epirubicin 10 mg mixed with saline 10 ml into the hepatic artery); GSMs-TACE group (n = 6), GSMs (20 mg) mixed with epirubicin solution (1 mg/ml); c-TACE group (n = 6), epirubicin (10 mg) mixed with lipiodol (10 ml). Each rabbit was administrated epirubicin at dose adjusted for a 1 mg/kg. Samples were collected from femoral vein at 5, 10, 20, 30, 40, 60, 90, and 120 min after therapy after 120 min; rabbit was killed, and tumor and peritumoral normal liver tissue was cised. Epirubicin concentrations in plasma and tumor were measured. The epirubicin concentration in plasma was significantly lower in GSMs-TACE group than in HAI group. C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively. The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively. Epirubicin concentration of GSMs-TACE group was significantly higher than that of HAI group (P < 0.05). The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively. The AUC was lower in GSMs-TACE group than in HAI group (P < 0.05). Compared with HAI, GSMs-TACE has higher epirubicin concentrations in tumor and lower concentrations in plasma. The results show that GSMs-TACE has a feature of slow drug release-it may be one of the mechanisms of GSMs-TACE for HCC.
本研究的目的是在兔VX2肝肿瘤肝动脉化疗栓塞(TACE)模型中研究明胶海绵微粒(GSMs)联合表柔比星的药代动力学。建立了18只新西兰白兔VX2成功模型,随机分为三组:肝动脉注射(HAI)组(n = 6),将表柔比星溶液(10 mg表柔比星与10 ml生理盐水混合后注入肝动脉);GSMs-TACE组(n = 6),GSMs(20 mg)与表柔比星溶液(1 mg/ml)混合;传统TACE组(c-TACE组,n = 6),表柔比星(10 mg)与碘油(10 ml)混合。每只兔子按1 mg/kg的剂量调整给予表柔比星。给药后120分钟,于5、10、20、30、40、60、90和120分钟从股静脉采集样本;处死兔子,切除肿瘤及肿瘤周围正常肝组织。测定血浆和肿瘤中的表柔比星浓度。GSMs-TACE组血浆中表柔比星浓度显著低于HAI组。给药后5分钟,三组的Cmax分别为:c-TACE组28.77±7.15 μg/ml,GSMs-TACE组83.84±32.28 μg/ml,HAI组238.46±23.44 μg/ml。肿瘤组织中表柔比星浓度分别为:c-TACE组53.06±16.9 μg/g,GSMs-TACE组44.49±16.80 μg/g,HAI组18.32±8.30 μg/g。GSMs-TACE组表柔比星浓度显著高于HAI组(P<0.05)。c-TACE组、GSMs-TACE组和HAI组0至120分钟的曲线下面积(AUC)分别为1,815±889.88、3,416±799.90和11,899±2,717.17 μg·min/ml。GSMs-TACE组的AUC低于HAI组(P<0.05)。与HAI相比,GSMs-TACE在肿瘤中的表柔比星浓度更高,而在血浆中的浓度更低。结果表明,GSMs-TACE具有药物缓释的特点——这可能是GSMs-TACE治疗肝癌的机制之一。